Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer: A population-based analysis

Yu Shan Lin, Chih Ching Yeh, Shiang Fu Huang, Yi Sheng Chou, Li Tang Kuo, Fung Chang Sung, Chih Hsin Muo, Chien Tien Su, Fu Hsiung Su

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

As reported by the Taiwan Cancer Registry in 2013 squamous cell carcinoma of head and neck cancer (HNSCC) was the sixth most frequently diagnosed cancer and the 5th most common cause of cancer related death and its incidence and mortality rate is still rising. The co-occurrence of HNSCC and secondary primary cancer (SPC) and the chemopreventive effect of aspirin on certain malignancies had been reported. Therefore we conducted this national study to investigate the use of aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer in Taiwan. We searched the Registry for Catastrophic Illness in the National Health Insurance Research Database (NHIRD) for 18,234 patients (3,576 aspirin users and 14,667 non-aspirin users) diagnosed with HNSCC during 2000–2005. The SPC incidence density during follow-up in 2000–2011 was compared between the groups. For HNSCC patients, aspirin use after diagnosis was significantly associated with SPC risk reduction by 25% (adjusted HR, 0.75; 95% CI, 0.63–0.89; p = 0.001) after multivariate analysis. In the subgroup analysis, we found that esophageal cancer and stomach cancer incidence were significantly reduced after aspirin use (adjusted HR, 0.60; 95% CI, 0.41–0.90; p = 0.01 for esophageal cancer; adjusted HR, 0.27; 95% CI, 0.08–0.87; p = 0.03 for stomach cancer). Aspirin use for 1–3 years was associated with SPC risk reduction by 35% (adjusted HR, 0.65; 95% CI, 0.49–0.87; p = 0.003). SPC risk reduction extended continuously for more than 3 years of follow up (adjusted HR, 0.72; 95% CI, 0.53–0.98; p = 0.030). Our data shows aspirin use was associated with reduced SPC incidence for HNSCC patients, attributed mainly to reduced risk of esophageal and stomach cancer.

Original languageEnglish
Article numbere0199014
JournalPLoS One
Volume13
Issue number8
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

aspirin
risk reduction
Risk Reduction Behavior
Head and Neck Neoplasms
Aspirin
neoplasms
Population
Neoplasms
esophageal neoplasms
stomach neoplasms
Stomach Neoplasms
Esophageal Neoplasms
incidence
Incidence
Health insurance
Taiwan
Registries
Catastrophic Illness
head and neck neoplasms
health insurance

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer : A population-based analysis. / Lin, Yu Shan; Yeh, Chih Ching; Huang, Shiang Fu; Chou, Yi Sheng; Kuo, Li Tang; Sung, Fung Chang; Muo, Chih Hsin; Su, Chien Tien; Su, Fu Hsiung.

In: PLoS One, Vol. 13, No. 8, e0199014, 01.08.2018.

Research output: Contribution to journalArticle

Lin, Yu Shan ; Yeh, Chih Ching ; Huang, Shiang Fu ; Chou, Yi Sheng ; Kuo, Li Tang ; Sung, Fung Chang ; Muo, Chih Hsin ; Su, Chien Tien ; Su, Fu Hsiung. / Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer : A population-based analysis. In: PLoS One. 2018 ; Vol. 13, No. 8.
@article{6f5eab0f357d49c7bb4b04020d3645a3,
title = "Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer: A population-based analysis",
abstract = "As reported by the Taiwan Cancer Registry in 2013 squamous cell carcinoma of head and neck cancer (HNSCC) was the sixth most frequently diagnosed cancer and the 5th most common cause of cancer related death and its incidence and mortality rate is still rising. The co-occurrence of HNSCC and secondary primary cancer (SPC) and the chemopreventive effect of aspirin on certain malignancies had been reported. Therefore we conducted this national study to investigate the use of aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer in Taiwan. We searched the Registry for Catastrophic Illness in the National Health Insurance Research Database (NHIRD) for 18,234 patients (3,576 aspirin users and 14,667 non-aspirin users) diagnosed with HNSCC during 2000–2005. The SPC incidence density during follow-up in 2000–2011 was compared between the groups. For HNSCC patients, aspirin use after diagnosis was significantly associated with SPC risk reduction by 25{\%} (adjusted HR, 0.75; 95{\%} CI, 0.63–0.89; p = 0.001) after multivariate analysis. In the subgroup analysis, we found that esophageal cancer and stomach cancer incidence were significantly reduced after aspirin use (adjusted HR, 0.60; 95{\%} CI, 0.41–0.90; p = 0.01 for esophageal cancer; adjusted HR, 0.27; 95{\%} CI, 0.08–0.87; p = 0.03 for stomach cancer). Aspirin use for 1–3 years was associated with SPC risk reduction by 35{\%} (adjusted HR, 0.65; 95{\%} CI, 0.49–0.87; p = 0.003). SPC risk reduction extended continuously for more than 3 years of follow up (adjusted HR, 0.72; 95{\%} CI, 0.53–0.98; p = 0.030). Our data shows aspirin use was associated with reduced SPC incidence for HNSCC patients, attributed mainly to reduced risk of esophageal and stomach cancer.",
author = "Lin, {Yu Shan} and Yeh, {Chih Ching} and Huang, {Shiang Fu} and Chou, {Yi Sheng} and Kuo, {Li Tang} and Sung, {Fung Chang} and Muo, {Chih Hsin} and Su, {Chien Tien} and Su, {Fu Hsiung}",
year = "2018",
month = "8",
day = "1",
doi = "10.1371/journal.pone.0199014",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

TY - JOUR

T1 - Aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer

T2 - A population-based analysis

AU - Lin, Yu Shan

AU - Yeh, Chih Ching

AU - Huang, Shiang Fu

AU - Chou, Yi Sheng

AU - Kuo, Li Tang

AU - Sung, Fung Chang

AU - Muo, Chih Hsin

AU - Su, Chien Tien

AU - Su, Fu Hsiung

PY - 2018/8/1

Y1 - 2018/8/1

N2 - As reported by the Taiwan Cancer Registry in 2013 squamous cell carcinoma of head and neck cancer (HNSCC) was the sixth most frequently diagnosed cancer and the 5th most common cause of cancer related death and its incidence and mortality rate is still rising. The co-occurrence of HNSCC and secondary primary cancer (SPC) and the chemopreventive effect of aspirin on certain malignancies had been reported. Therefore we conducted this national study to investigate the use of aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer in Taiwan. We searched the Registry for Catastrophic Illness in the National Health Insurance Research Database (NHIRD) for 18,234 patients (3,576 aspirin users and 14,667 non-aspirin users) diagnosed with HNSCC during 2000–2005. The SPC incidence density during follow-up in 2000–2011 was compared between the groups. For HNSCC patients, aspirin use after diagnosis was significantly associated with SPC risk reduction by 25% (adjusted HR, 0.75; 95% CI, 0.63–0.89; p = 0.001) after multivariate analysis. In the subgroup analysis, we found that esophageal cancer and stomach cancer incidence were significantly reduced after aspirin use (adjusted HR, 0.60; 95% CI, 0.41–0.90; p = 0.01 for esophageal cancer; adjusted HR, 0.27; 95% CI, 0.08–0.87; p = 0.03 for stomach cancer). Aspirin use for 1–3 years was associated with SPC risk reduction by 35% (adjusted HR, 0.65; 95% CI, 0.49–0.87; p = 0.003). SPC risk reduction extended continuously for more than 3 years of follow up (adjusted HR, 0.72; 95% CI, 0.53–0.98; p = 0.030). Our data shows aspirin use was associated with reduced SPC incidence for HNSCC patients, attributed mainly to reduced risk of esophageal and stomach cancer.

AB - As reported by the Taiwan Cancer Registry in 2013 squamous cell carcinoma of head and neck cancer (HNSCC) was the sixth most frequently diagnosed cancer and the 5th most common cause of cancer related death and its incidence and mortality rate is still rising. The co-occurrence of HNSCC and secondary primary cancer (SPC) and the chemopreventive effect of aspirin on certain malignancies had been reported. Therefore we conducted this national study to investigate the use of aspirin associated with risk reduction of secondary primary cancer for patients with head and neck cancer in Taiwan. We searched the Registry for Catastrophic Illness in the National Health Insurance Research Database (NHIRD) for 18,234 patients (3,576 aspirin users and 14,667 non-aspirin users) diagnosed with HNSCC during 2000–2005. The SPC incidence density during follow-up in 2000–2011 was compared between the groups. For HNSCC patients, aspirin use after diagnosis was significantly associated with SPC risk reduction by 25% (adjusted HR, 0.75; 95% CI, 0.63–0.89; p = 0.001) after multivariate analysis. In the subgroup analysis, we found that esophageal cancer and stomach cancer incidence were significantly reduced after aspirin use (adjusted HR, 0.60; 95% CI, 0.41–0.90; p = 0.01 for esophageal cancer; adjusted HR, 0.27; 95% CI, 0.08–0.87; p = 0.03 for stomach cancer). Aspirin use for 1–3 years was associated with SPC risk reduction by 35% (adjusted HR, 0.65; 95% CI, 0.49–0.87; p = 0.003). SPC risk reduction extended continuously for more than 3 years of follow up (adjusted HR, 0.72; 95% CI, 0.53–0.98; p = 0.030). Our data shows aspirin use was associated with reduced SPC incidence for HNSCC patients, attributed mainly to reduced risk of esophageal and stomach cancer.

UR - http://www.scopus.com/inward/record.url?scp=85052096780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052096780&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0199014

DO - 10.1371/journal.pone.0199014

M3 - Article

AN - SCOPUS:85052096780

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 8

M1 - e0199014

ER -